Atlas Trials

A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment

Clinical trial NCT01136733 · COMPLETED

Trial details

NCT number
NCT01136733
Sponsor
Eisai Inc.
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Metastatic Renal Cell Carcinoma
Start date
2010-08-05
Primary completion
2014-06-13
Enrollment
173

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.